Literature DB >> 2015912

Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins.

J Tözsér1, I Bláha, T D Copeland, E M Wondrak, S Oroszlan.   

Abstract

The substrate specificity of the human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) proteinases was compared using oligopeptides corresponding to cleavage sites in the Gag and Gag-Pol polyproteins of both viruses. All peptides mimicking cleavage sites at the junction of major functional protein domains were correctly cleaved by both enzymes. However, some other peptides thought to represent secondary cleavage sites remained intact. The kinetic parameters (Km and kcat) obtained for the different substrates showed several hundred-fold variation but were similar for the same substrate.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2015912     DOI： 10.1016/0014-5793(91)80362-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  59 in total

1.  Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N-end-rule pathway.

Authors:  P O Falnes; R Welker; H G Kräusslich; S Olsnes
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

2.  Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.

Authors:  Deborah S Dauber; Rainer Ziermann; Neil Parkin; Dustin J Maly; Sami Mahrus; Jennifer L Harris; Jon A Ellman; Christos Petropoulos; Charles S Craik
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

3.  Structural, kinetic, and thermodynamic studies of specificity designed HIV-1 protease.

Authors:  Oscar Alvizo; Seema Mittal; Stephen L Mayo; Celia A Schiffer
Journal:  Protein Sci       Date:  2012-06-05       Impact factor: 6.725

4.  The substrate specificity of Metarhizium anisopliae and Bos taurus carboxypeptidases A: insights into their use as tools for the removal of affinity tags.

Authors:  Brian P Austin; József Tözsér; Péter Bagossi; Joseph E Tropea; David S Waugh
Journal:  Protein Expr Purif       Date:  2010-11-10       Impact factor: 1.650

5.  Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.

Authors:  Yunfeng Tie; Peter I Boross; Yuan-Fang Wang; Laquasha Gaddis; Fengling Liu; Xianfeng Chen; Jozsef Tozser; Robert W Harrison; Irene T Weber
Journal:  FEBS J       Date:  2005-10       Impact factor: 5.542

6.  HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions.

Authors:  Isabel Olivares; Alok Mulky; Peter I Boross; József Tözsér; John C Kappes; Cecilio López-Galíndez; Luis Menéndez-Arias
Journal:  J Mol Biol       Date:  2007-07-03       Impact factor: 5.469

7.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Identification of structural mechanisms of HIV-1 protease specificity using computational peptide docking: implications for drug resistance.

Authors:  Sidhartha Chaudhury; Jeffrey J Gray
Journal:  Structure       Date:  2009-12-09       Impact factor: 5.006

10.  Infection of a yellow baboon with simian immunodeficiency virus from African green monkeys: evidence for cross-species transmission in the wild.

Authors:  M J Jin; J Rogers; J E Phillips-Conroy; J S Allan; R C Desrosiers; G M Shaw; P M Sharp; B H Hahn
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.